*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Heart failure in oncological patients

Author: , N.A.SHANAZAROV , N.K. SEIDALIN, A.F. KHALIRAKHMANOV, A.Z. SHARAFEEV, G.D. GATUYATULLINA, S.V. ZINCHENKO
Abstract: The purpose of the study is to conduct a systematic analysis of data from various literature sources on the role of heart failure in the development of cancer, as well as to consider the problems of diagnosis and treatment of heart failure in patients with cancer. Materials and methods. A review of the literature in the Cochrane Library, Elibrary, and PubMed systems over the past 8 years, which examines common risk factors and mechanisms of heart failure (HF) and malignant neoplasms (MN) has been conducted. RESULTS: Analysis of literature data shows that cardiovascular diseases and cancer have common risk factors. Several common pathophysiological mechanisms have been identified that link heart failure (HF) to the cancer process. These include inflammation, oxidative stress, and neurohormonal activation. HF is currently known as a frequent complication of aggressive cardiotoxic antitumor therapy, which can worsen the course of existing HF or cause its development. Recent epidemiological and experimental analyses show that the development of cancer is more common among patients with pre-existing HF. Although the cause of this relationship has not yet been identified, it is assumed that heart failure may be a Pro-oncogenic condition. Conclusion. Until now, the main focus of cardioncology has been prevention and treatment of cardiotoxic effects of chemotherapeutic drugs. In this context, elucidating the underlying mechanisms plays an important role in developing strategies to prevent chemotherapy-related cardiomyopathy. However, it is necessary to pay attention to the fact that there is more and more evidence that patients with heart failure have a high risk of developing cancer pathology, thereby requiring more attention. In General, understanding the direct and indirect mechanisms of the relationship between HF and MN can help in the prevention and early diagnosis of these diseases.
Keyword: cardioncology, heart failure, malignant neoplasms, cardiotoxicity, chemotherapy, cancer.
DOI: https://doi.org/10.31838/ijpr/2020.12.03.419
Download: Request For Article
 
Clients

Clients

Clients

Clients

Clients
ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free